BioCardia (NASDAQ:BCDA) Issues Quarterly Earnings Results

BioCardia (NASDAQ:BCDA) released its earnings results on Wednesday. The company reported ($0.25) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.87) by $0.62, Zacks reports.

BioCardia Stock Down 3.0 %

BCDA stock traded down $0.08 during trading hours on Wednesday, hitting $2.55. The company’s stock had a trading volume of 39,519 shares, compared to its average volume of 272,901. The company has a market capitalization of $11.69 million, a PE ratio of -0.61 and a beta of 1.28. The stock has a 50 day moving average price of $2.43 and a two-hundred day moving average price of $2.41. BioCardia has a 12 month low of $1.63 and a 12 month high of $6.41.

Analyst Ratings Changes

A number of equities analysts have recently weighed in on BCDA shares. Alliance Global Partners raised shares of BioCardia from a “hold” rating to a “strong-buy” rating in a research note on Thursday, January 30th. HC Wainwright reiterated a “buy” rating and set a $25.00 price target on shares of BioCardia in a report on Wednesday, December 18th.

Insider Activity at BioCardia

In other BioCardia news, Director Simon H. Stertzer bought 22,753 shares of the stock in a transaction on Monday, March 3rd. The shares were purchased at an average cost of $2.30 per share, with a total value of $52,331.90. Following the completion of the transaction, the director now directly owns 40,602 shares of the company’s stock, valued at $93,384.60. This represents a 127.47 % increase in their position. The purchase was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. In the last 90 days, insiders acquired 25,353 shares of company stock valued at $58,525. Insiders own 20.00% of the company’s stock.

BioCardia Company Profile

BioCardia, Inc, a clinical-stage regenerative medicine company, develops cellular and cell-derived therapeutics for cardiovascular and pulmonary diseases in the United States. Its lead product candidate is CardiAMP, an autologous mononuclear cell therapy system in Phase III clinical trial for the treatment of ischemic heart failure with reduced ejection fraction and refractory angina resulting from chronic myocardial ischemia.